Trademark: 97313068
Word
WEZENLA
Status Date
Friday, April 12, 2024
Filing Date
Tuesday, March 15, 2022
Published for Opposition
Tuesday, April 4, 2023
5 pharmaceutical preparations and substances for use in the treatment of hematological, immune, autoimmune, inflammatory and respiratory diseases and disorders; pharmaceutical preparations and substances for the treatment of cancer and cardiovascular diseases and disorders; pharmaceutical preparations and substances used for the treatment of blood cells and blood vessel diseases and disorders; pharmaceutical preparations and substances for the treatment of oncological, and ophthalmic diseases and disorders; pharmaceutical preparations and substances for the treatment of inflammatory disorders of the central nervous system; pharmaceutical preparations and substances used for the treatment of hemolytic anemia, thrombocytopenia and kidney failure
Dec 21, 2022
Non-Final Action E-Mailed
Mar 18, 2022
New Application Entered
Mar 21, 2022
New Application Office Supplied Data Entered
Dec 14, 2022
Assigned To Examiner
Dec 21, 2022
Non-Final Action Written
Dec 21, 2022
Notification Of Non-Final Action E-Mailed
Feb 20, 2023
Teas Response To Office Action Received
Feb 20, 2023
Correspondence Received In Law Office
Feb 21, 2023
Teas/Email Correspondence Entered
Feb 28, 2023
Approved For Pub - Principal Register
Mar 15, 2023
Notification Of Notice Of Publication E-Mailed
Apr 4, 2023
Published For Opposition
Apr 4, 2023
Official Gazette Publication Confirmation E-Mailed
May 30, 2023
Noa E-Mailed - Sou Required From Applicant
Oct 2, 2023
Sou Teas Extension Received
Oct 4, 2023
Notice Of Approval Of Extension Request E-Mailed
Oct 2, 2023
Sou Extension 1 Filed
Oct 2, 2023
Sou Extension 1 Granted
Apr 12, 2024
Sou Teas Extension Received
Apr 12, 2024
Sou Extension 2 Filed
Apr 12, 2024
Sou Extension 2 Granted
Apr 13, 2024
Notice Of Approval Of Extension Request E-Mailed
Trademark Alertz updated from USPTO on 2030-01-24
